Status:
COMPLETED
Pro-Resolving Mediators in Acute Inflammation in Humans
Lead Sponsor:
Brigham and Women's Hospital
Collaborating Sponsors:
National Institute of General Medical Sciences (NIGMS)
Conditions:
Inflammation; Skin
Resolution
Eligibility:
All Genders
18-64 years
Phase:
EARLY_PHASE1
Brief Summary
The investigators are undertaking a clinical blister model with or without dietary supplementation with omega-3 fatty acids (i.e., Lovaza) to determine the role of specialized pro-resolving mediators ...
Detailed Description
The specific aims of this study are based on the hypothesis that in health, natural pro-resolving mechanisms, including specialized pro-resolving mediators and cellular effectors, are generated to pro...
Eligibility Criteria
Inclusion
- Healthy adults
- Ages 18-64
Exclusion
- Known acute or chronic infection
- Known acute or chronic disease of any kind
- Known allergy to fish or shellfish
- Use of any prescription medication
- Use of over-the-counter medication except multivitamins
- Use of dietary or herbal supplement except protein supplements
- Women that are pregnant, trying to become pregnant, or breastfeeding
- Any skin disease
- Known immunocompromise, HIV, or Diabetes mellitus
- History of cardiopulmonary disease
- History of upper extremity cellulitis
- Significant allergy of any kind
- Known bleeding diathesis
- History of keloid scar formation
- Forearm tattoo
- Use of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) during study or within 2 weeks prior to enrollment.
Key Trial Info
Start Date :
July 2 2018
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 22 2022
Estimated Enrollment :
19 Patients enrolled
Trial Details
Trial ID
NCT04308889
Start Date
July 2 2018
End Date
February 22 2022
Last Update
May 26 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Brigham and Women's Hospital
Boston, Massachusetts, United States, 02115